Celltrion, Inc.

Celltrion has outlined a multi-phase strategy to mitigate risks from evolving US pharmaceutical tariffs, anchored by its selection as the preferred bidder for the acquisition of a large-scale cGMP bio

Celltrion has become the third firm to launch denosumab biosimilars in the US, announcing that its Stoboclo and Osenvelt (denosumab-bmwo) rivals to Amgen’s Prolia and Xgeva are now commercially availa

Celltrion expects US President Donald Trump’s latest executive order aimed at lowering US prescription drug prices to levels in other reference countries to have a positive impact on the biosimilars i

The US Food and Drug Administration has deemed Celltrion’s Yuflyma (adalimumab-aaty) as interchangeable with the originator Humira. The interchangeability designation comes almost two years after Yufl